Brief: Advaxis Presents Updated Data From Ongoing ADXS-503 Phase 1/2 Lung Cancer Trial At 2020 SITC

Ayala Pharmaceuticals

09/11/2020 14:20

Nov 9 (Reuters) - Advaxis Inc  ADXS.O :
    * ADVAXIS INC - PRESENTS UPDATED DATA FROM ONGOING ADXS-503
PHASE
1/2 LUNG CANCER TRIAL AT 2020 SOCIETY FOR IMMUNOTHERAPY OF
CANCER (SITC) ANNUAL MEETING
    * ADVAXIS INC - ADXS-503 APPEARED SAFE AND WELL TOLERATED AS
A
MONOTHERAPY AND IN COMBINATION WITH KEYTRUDA
    * ADVAXIS - DISEASE CONTROL RATE OF 67% AND OVERALL RESPONSE
RATE
OF 17% IN FIRST SIX EVALUABLE PATIENTS WITH IMMEDIATE PRIOR
PROGRESSION ON KEYTRUDA
    * ADVAXIS INC - BIOMARKER DATA CONFIRMS ON-MECHANISM
ACTIVATION OF
INNATE AND ADAPTIVE IMMUNE RESPONSES TO ADXS-503

Source text for Eikon:  ID:nGNX562nDZ 
Further company coverage:  ADXS.O 

 ((Reuters.Briefs@thomsonreuters.com;))